Rated 2.1 / 5 (How Ratings Work)
Possible to probable range of efficacy of cannabis for treatment of huntington's disease.
Based on 34 Studies from 1986 - 2017
Study Name, Description & Year
Rating
Effects Of A Sativex-Like Combination Of Phytocannabinoids On Disease Progression In R6/2 Mice, An Experimental Model Of Huntington’s Disease
Animal study (mice) — 2017
Neurological Aspects Of Medical Use Of Cannabidiol
Review/Meta-Analysis — 2017
Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability In A Cell Culture Model Of Huntington Disease
Laboratory Study — 2016
ENDOCANNABINOID SYSTEM: A Multi-facet Therapeutic Target
Review — 2016
Amyloid Proteotoxicity Initiates An Inflammatory Response Blocked By Cannabinoids
Laboratory Study — 2016
Endocannabionoid System In Neurological Disorders
Review — 2016
Chronic Cannabinoid Receptor Stimulation Selectively Prevents Motor Impairments In A Mouse Model Of Huntington's Disease.
Animal study (mice) — 2015
Neuroprotective Properties Of Cannabigerol In Huntington's Disease: Studies In R6/2 Mice And 3-nitropropionate-lesioned Mice
Animal study (mice) — 2015
Cannabinoids In Neurodegenerative Disorders And Stroke/Brain Trauma: From Preclinical Models To Clinical Applications
Review — 2015
A Restricted Population Of CB1 Cannabinoid Receptors With Neuroprotective Activity.
Animal study (mice) — 2014
The Cytokine And Endocannabinoid Systems Are Co-regulated By NF-κB P65/RelA In Cell Culture And Transgenic Mouse Models Of Huntington's Disease And In Striatal Tissue From Huntington's Disease Patients
Animal study (mice) — 2014
Cannabinoids Increase Type 1 Cannabinoid Receptor Expression In A Cell Culture Model Of Striatal Neurons: Implications For Huntington's Disease
Laboratory Study — 2013
Sativex-like Combination Of Phytocannabinoids Is Neuroprotective In Malonate-lesioned Rats, An Inflammatory Model Of Huntington's Disease: Role Of CB1 And CB2 Receptors
Animal study (rats) — 2012
Unbalance Of CB1 Receptors Expressed In GABAergic And Glutamatergic Neurons In A Transgenic Mouse Model Of Huntington's Disease
Animal study (mice) — 2012
Neuroprotective Effects Of Phytocannabinoid-based Medicines In Experimental Models Of Huntington's Disease
Animal model (rats) — 2011
Prospects For Cannabinoid Therapies In Basal Ganglia Disorders
Meta-analysis and review — 2011
Loss Of Striatal Type 1 Cannabinoid Receptors Is A Key Pathogenic Factor In Huntington's Disease
Animal study (mice) — 2011
Cannabinoid Receptors And Endocannabinoids: Role In Neuroinflammatory And Neurodegenerative Disorders
Literature review — 2010
Behavioural And Molecular Consequences Of Chronic Cannabinoid Treatment In Huntington's Disease Transgenic Mice.
Animal study (mice) — 2010
Neuroprotective Potential Of CB1 Receptor Agonists In An In Vitro Model Of Huntington's Disease
Laboratory Study — 2010
A Pilot Study Using Nabilone For Symptomatic Treatment In Huntington's Disease
Double-blind, placebo-controlled, cross-over study of nabilone versus placebo. — 2009
Cannabinoid CB2 Receptor Agonists Protect The Striatum Against Malonate Toxicity: Relevance For Huntington's Disease
Animal study (rats) — 2009
Cannabidiol Reduced The Striatal Atrophy Caused 3-nitropropionic Acid In Vivo By Mechanisms Independent Of The Activation Of Cannabinoid, Vanilloid TRPV1 And Adenosine A2A Receptors
Animal study (rats) — 2007
The Endocannabinoid System And Huntington's Disease
Review — 2003
Effects Of Cannabinoids In The Rat Model Of Huntington's Disease Generated By An Intrastriatal Injection Of Malonate
Animal study (rats) — 2003
Alleviation Of Motor Hyperactivity And Neurochemical Deficits By Endocannabinoid Uptake Inhibition In A Rat Model Of Huntington's Disease
Animal study (rats) — 2002
Changes In Endocannabinoid Transmission In The Basal Ganglia In A Rat Model Of Huntington's Disease
Animal study (rats) — 2001
The Pattern Of Neurodegeneration In Huntington's Disease: A Comparative Study Of Cannabinoid, Dopamine, Adenosine And GABA(A) Receptor Alterations In The Human Basal Ganglia In Huntington's Disease
Laboratory Study — 2000
Loss Of Cannabinoid Receptors In The Substantia Nigra In Huntington's Disease.
Autoradiography review of healthy human brain compared with Huntington affected brains. — 1993
Controlled Clinical Trial Of Cannabidiol In Huntington's Disease
15 patients with Huntington’s Disease — 1991
Effects Of Cannabidiol In Huntington’s Disease
Three patients, 30 to 56, had HD for 7 to 12 ages years’ duration — 1986